Currently Viewing:
Newsroom
Currently Reading
What We're Reading: States to Recalibrate Hospital Payments; Mumps Outbreak; Tuberculosis Eradication Plan
March 21, 2019 – AJMC Staff
Novo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable
March 21, 2019 – Mary Caffrey and Samantha DiGrande
Continuing Systemic Treatment in Cutaneous T-cell Lymphoma Associated With Lower Healthcare Costs
March 20, 2019 – Mary Caffrey
Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer
March 20, 2019 – Laura Joszt
Adherence to COPD Treatment Lower With 3 Inhalers Compared With 2
March 20, 2019 – Jaime Rosenberg
CDC Says New HIV Transmissions Stem From Lack of Treatment, Unawareness of Infection
March 20, 2019 – Wallace Stephens
What We're Reading: Postpartum Depression Drug Approval; Marijuana and Psychosis; Mississippi Abortion Bill
March 20, 2019 – AJMC Staff
AHIP, Employer Groups Seek Congressional Action on Surprise Medical Bills
March 19, 2019 – Allison Inserro
The Current Landscape of CGRP Inhibitor Coverage
March 19, 2019 – Samantha DiGrande

AJMC® in the Press, November 9, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
OBR Oncology’s Thursday daily newsfeed included an article from The American Journal of Managed Care® (AJMC®). The article, “Azar Announces Mandatory Oncology Payment Model is Coming,” covered the HHS secretary’s announcement that the administration will revisit mandatory models that it had previously scrapped in cardiac care and that the time had come for “exploring new and improved episode-based models in other areas, including radiation oncology.”

AJMC®’s The Center for Biosimilars®’ article “FDA Approves Coherus’ Pegfilgrastim Biosimilar, Udenyca” was highlighted in OBR Oncology's Monday daily newsfeed. The article reported that, after previous US regulatory setbacks, the manufacturer had gained approval for its biosimilar, referencing Neulasta, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!